Tigress Financial Maintains Buy on Medline, Raises Price Target to $62
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $60 to $62.
Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $60 to $62.